Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma

Young Joon Yoon, Kwang Hyub Han, Chul Kim, Chae Yoon Chon, Young Myoung Moon, Chang Hoon Han, Hye Jin Choi, Yong Soo Kim, Jae Yong Han, Hyon Suk Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Protein induced by vitamin K absence or antagonist II (PIVKA-II) appears to be a useful tumor marker for the evaluation of patients with hepatocellular carcinoma (HCC). But the usefulness of PIVKA-II was not yet clear in Korea where hepatitis B-virus is endemic. We investigated the usefulness of PIVKA-II in the diagnosis and follow-up after treatment of HCC. METHODS: We studied patients with HCC which was pathologically confirmed. PIVKA-II was measured by enzyme immunoassay. PIVKA- levels before and after treatment, in correlation with imaging studies, were analyzed for the comparison of treatment responses. Kappa index was obtained. RESULTS: A total of 129 patients were included. 93 patients (72%) were HBsAg positive. 86 patients (67%) were PIVKA-II >40 mAU/mL. 52 patients (40%) were AFP >20 ng/mL and 77 patients (60%) were AFP < or = 20 ng/mL. Of 77 patients, 40 patients (52%) showed PIVKA-II >40 mAU/mL. 68 of 129 patients were evaluated treatment response. On the basis of radiologic response, CR was 33, PR 17, SD 12, and PD 6. Of the 33 radiologic CR patients, 30 patients were CR and 3 patients were PR by means of PIVKA-II response. Of the 17 radiologic PR patients, 6 patients were CR and 7 patients were PR. Therefore, tumor responses by radiologic and PIVKA-II were well correlated (Kappa index was 0.59). CONCLUSIONS: PIVKA-II can be used as a useful tumor marker for patients with HCC, especially those with low levels of AFP, before and after treatment in Korea.

Original languageEnglish
Pages (from-to)465-471
Number of pages7
JournalTaehan Kan Hakhoe chi = The Korean journal of hepatology
Volume8
Issue number4
Publication statusPublished - 2002 Dec

Fingerprint

Blood Proteins
Hepatocellular Carcinoma
Therapeutics
acarboxyprothrombin
Korea
Tumor Biomarkers
Hepatitis B Surface Antigens
Immunoenzyme Techniques
Hepatitis B virus

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yoon, Young Joon ; Han, Kwang Hyub ; Kim, Chul ; Chon, Chae Yoon ; Moon, Young Myoung ; Han, Chang Hoon ; Choi, Hye Jin ; Kim, Yong Soo ; Han, Jae Yong ; Kim, Hyon Suk. / Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma. In: Taehan Kan Hakhoe chi = The Korean journal of hepatology. 2002 ; Vol. 8, No. 4. pp. 465-471.
@article{ed74363d1f564398b354f929ca24fa6a,
title = "Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma",
abstract = "BACKGROUND/AIMS: Protein induced by vitamin K absence or antagonist II (PIVKA-II) appears to be a useful tumor marker for the evaluation of patients with hepatocellular carcinoma (HCC). But the usefulness of PIVKA-II was not yet clear in Korea where hepatitis B-virus is endemic. We investigated the usefulness of PIVKA-II in the diagnosis and follow-up after treatment of HCC. METHODS: We studied patients with HCC which was pathologically confirmed. PIVKA-II was measured by enzyme immunoassay. PIVKA- levels before and after treatment, in correlation with imaging studies, were analyzed for the comparison of treatment responses. Kappa index was obtained. RESULTS: A total of 129 patients were included. 93 patients (72{\%}) were HBsAg positive. 86 patients (67{\%}) were PIVKA-II >40 mAU/mL. 52 patients (40{\%}) were AFP >20 ng/mL and 77 patients (60{\%}) were AFP < or = 20 ng/mL. Of 77 patients, 40 patients (52{\%}) showed PIVKA-II >40 mAU/mL. 68 of 129 patients were evaluated treatment response. On the basis of radiologic response, CR was 33, PR 17, SD 12, and PD 6. Of the 33 radiologic CR patients, 30 patients were CR and 3 patients were PR by means of PIVKA-II response. Of the 17 radiologic PR patients, 6 patients were CR and 7 patients were PR. Therefore, tumor responses by radiologic and PIVKA-II were well correlated (Kappa index was 0.59). CONCLUSIONS: PIVKA-II can be used as a useful tumor marker for patients with HCC, especially those with low levels of AFP, before and after treatment in Korea.",
author = "Yoon, {Young Joon} and Han, {Kwang Hyub} and Chul Kim and Chon, {Chae Yoon} and Moon, {Young Myoung} and Han, {Chang Hoon} and Choi, {Hye Jin} and Kim, {Yong Soo} and Han, {Jae Yong} and Kim, {Hyon Suk}",
year = "2002",
month = "12",
language = "English",
volume = "8",
pages = "465--471",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "4",

}

Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma. / Yoon, Young Joon; Han, Kwang Hyub; Kim, Chul; Chon, Chae Yoon; Moon, Young Myoung; Han, Chang Hoon; Choi, Hye Jin; Kim, Yong Soo; Han, Jae Yong; Kim, Hyon Suk.

In: Taehan Kan Hakhoe chi = The Korean journal of hepatology, Vol. 8, No. 4, 12.2002, p. 465-471.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma

AU - Yoon, Young Joon

AU - Han, Kwang Hyub

AU - Kim, Chul

AU - Chon, Chae Yoon

AU - Moon, Young Myoung

AU - Han, Chang Hoon

AU - Choi, Hye Jin

AU - Kim, Yong Soo

AU - Han, Jae Yong

AU - Kim, Hyon Suk

PY - 2002/12

Y1 - 2002/12

N2 - BACKGROUND/AIMS: Protein induced by vitamin K absence or antagonist II (PIVKA-II) appears to be a useful tumor marker for the evaluation of patients with hepatocellular carcinoma (HCC). But the usefulness of PIVKA-II was not yet clear in Korea where hepatitis B-virus is endemic. We investigated the usefulness of PIVKA-II in the diagnosis and follow-up after treatment of HCC. METHODS: We studied patients with HCC which was pathologically confirmed. PIVKA-II was measured by enzyme immunoassay. PIVKA- levels before and after treatment, in correlation with imaging studies, were analyzed for the comparison of treatment responses. Kappa index was obtained. RESULTS: A total of 129 patients were included. 93 patients (72%) were HBsAg positive. 86 patients (67%) were PIVKA-II >40 mAU/mL. 52 patients (40%) were AFP >20 ng/mL and 77 patients (60%) were AFP < or = 20 ng/mL. Of 77 patients, 40 patients (52%) showed PIVKA-II >40 mAU/mL. 68 of 129 patients were evaluated treatment response. On the basis of radiologic response, CR was 33, PR 17, SD 12, and PD 6. Of the 33 radiologic CR patients, 30 patients were CR and 3 patients were PR by means of PIVKA-II response. Of the 17 radiologic PR patients, 6 patients were CR and 7 patients were PR. Therefore, tumor responses by radiologic and PIVKA-II were well correlated (Kappa index was 0.59). CONCLUSIONS: PIVKA-II can be used as a useful tumor marker for patients with HCC, especially those with low levels of AFP, before and after treatment in Korea.

AB - BACKGROUND/AIMS: Protein induced by vitamin K absence or antagonist II (PIVKA-II) appears to be a useful tumor marker for the evaluation of patients with hepatocellular carcinoma (HCC). But the usefulness of PIVKA-II was not yet clear in Korea where hepatitis B-virus is endemic. We investigated the usefulness of PIVKA-II in the diagnosis and follow-up after treatment of HCC. METHODS: We studied patients with HCC which was pathologically confirmed. PIVKA-II was measured by enzyme immunoassay. PIVKA- levels before and after treatment, in correlation with imaging studies, were analyzed for the comparison of treatment responses. Kappa index was obtained. RESULTS: A total of 129 patients were included. 93 patients (72%) were HBsAg positive. 86 patients (67%) were PIVKA-II >40 mAU/mL. 52 patients (40%) were AFP >20 ng/mL and 77 patients (60%) were AFP < or = 20 ng/mL. Of 77 patients, 40 patients (52%) showed PIVKA-II >40 mAU/mL. 68 of 129 patients were evaluated treatment response. On the basis of radiologic response, CR was 33, PR 17, SD 12, and PD 6. Of the 33 radiologic CR patients, 30 patients were CR and 3 patients were PR by means of PIVKA-II response. Of the 17 radiologic PR patients, 6 patients were CR and 7 patients were PR. Therefore, tumor responses by radiologic and PIVKA-II were well correlated (Kappa index was 0.59). CONCLUSIONS: PIVKA-II can be used as a useful tumor marker for patients with HCC, especially those with low levels of AFP, before and after treatment in Korea.

UR - http://www.scopus.com/inward/record.url?scp=2342653067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342653067&partnerID=8YFLogxK

M3 - Article

C2 - 12506251

AN - SCOPUS:2342653067

VL - 8

SP - 465

EP - 471

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 4

ER -